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Tyrosine hydroxylase catalyses the hydroxylation of L-tyrosine to L-DOPA, the rate-limiting step in the synthesis of catechol-
amines. Mutations in the TH gene encoding tyrosine hydroxylase are associated with the autosomal recessive disorder tyrosine
hydroxylase deﬁciency, which manifests phenotypes varying from infantile parkinsonism and DOPA-responsive dystonia, also
termed type A, to complex encephalopathy with perinatal onset, termed type B. We generated homozygous Th knock-in mice
with the mutation Th-p.R203H, equivalent to the most recurrent human mutation associated with type B tyrosine hydroxylase
deﬁciency (TH-p.R233H), often unresponsive to L-DOPA treatment. The Th knock-in mice showed normal survival and food
intake, but hypotension, hypokinesia, reduced motor coordination, wide-based gate and catalepsy. This phenotype was associated
with a gradual loss of central catecholamines and the serious manifestations of motor impairment presented diurnal ﬂuctuation but
did not improve with standard L-DOPA treatment. The mutant tyrosine hydroxylase enzyme was unstable and exhibited deﬁcient
stabilization by catecholamines, leading to decline of brain tyrosine hydroxylase-immunoreactivity in the Th knock-in mice. In fact
the substantia nigra presented an almost normal level of mutant tyrosine hydroxylase protein but distinct absence of the enzyme
was observed in the striatum, indicating a mutation-associated mislocalization of tyrosine hydroxylase in the nigrostriatal pathway.
This hypomorphic mouse model thus provides understanding on pathomechanisms in type B tyrosine hydroxylase deﬁciency and a
platform for the evaluation of novel therapeutics for movement disorders with loss of dopaminergic input to the striatum.
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Introduction
Tyrosine hydroxylase (TH; EC 1.14.16.2) is a homo-
tetrameric enzyme that catalyses the conversion of
L-tyrosine to L-dihydroxyphenylalanine (L-DOPA) by using
molecular oxygen as additional substrate and the cofactor
(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) (Nagatsu
et al., 1964; Roberts and Fitzpatrick, 2013). This hydrox-
ylation is the rate-limiting step in the synthesis of the cat-
echolamine neurotransmitters dopamine, norepinephrine
and epinephrine (Nagatsu et al., 1964). Dopamine is dis-
tinctively involved in motor control, but also in cognition,
memory and reward and, as a precursor of norepinephrine
and epinephrine, indirectly regulates attention and helps to
maintain normal blood pressure and blood sugar
(Eisenhofer et al., 2004). In the CNS, TH is mainly
expressed in dopaminergic neurons of the substantia
nigra, which project mostly to the striatum and have a
central role in motor control, and in the ventral tegmental
area, which projects to the nucleus accumbens and the pre-
frontal cortex and regulates motivation and reward. TH is
also expressed in noradrenergic neurons of the locus coer-
uleus and lateral tegmental system (Zigmond et al., 1989;
Bjorklund and Dunnett, 2007). Outside the CNS, TH
expression is found in the adrenal medulla, the sympathetic
neurons, and in non-neuronal (renal, intestine, pancreatic
and lymphoid) tissues. The single human TH gene under-
goes alternative mRNA splicing generating four main iso-
forms (hTH1–hTH4), with variations in the length of the
N-terminal, where hTH4 corresponds to the longest, full-
length isoform and hTH1 to the shortest and most abun-
dant one, equivalent to rodent TH (Nagatsu, 1995). TH
activity is tightly controlled by regulatory mechanisms at
the transcriptional, translational and post-translational
levels (Kumer and Vrana, 1996; Tank et al., 2008).
The latter includes phosphorylation at several Ser/Thr resi-
dues at the N-terminal tail (Daubner et al., 2011). Notably,
phosphorylation at Ser40 by cAMP-dependent protein
kinase A activates TH by releasing the feedback inhibition
of catecholamines and decreasing the Km for the cofactor
BH4 (Nagatsu et al., 1964). Binding of the catecholamine
end-products inactivates and stabilizes TH both in vitro
(Okuno and Fujisawa, 1991; Martinez et al., 1996) and
in vivo (Sumi-Ichinose et al., 2001). Another short-term
regulatory mechanism of TH of important biological sig-
niﬁcance is substrate inhibition, that allows steady synthesis
of dopamine despite ﬂuctuations in blood L-tyrosine (Reed
et al., 2010).
Mutations in the TH gene (OMIM *191290) cause TH
deﬁciency (THD; OMIM #605407), which is a rare dis-
order that comprises a broad phenotypic variation includ-
ing infantile parkinsonism and L-DOPA-responsive dystonia
(DRD). THD manifestations range from a mild progressive
limb dystonia, postural tremor and hypokinetic rigid syn-
drome that is responsive to L-DOPA (termed type A) to a
progressive and complex neonatal or early-infancy onset
encephalopathy with L-DOPA-unresponsive parkinsonism
(termed type B) (Willemsen et al., 2010). A certain geno-
type–phenotype correlation between the clinical subtype
and the genotype of the THD patients through the
in vitro TH activity of the mutant variants has recently
been reported (Fossbakk et al., 2014). Nevertheless, an
accurate clinical diagnosis of THD must be based on
central catecholamine deﬁciency reﬂected by normal
5-hydroxyindolacetic acid (5-HIAA) but low homovanillic
acid (HVA), low 3-methoxy-4-hydroxyphenylethylene
glycol (MHPG) and low HVA:5-HIAA ratio in CSF
from lumbar puncture (Willemsen et al., 2010), and by
mutation analysis of the TH gene (Haavik et al., 2008;
Kurian et al., 2011). Peripheral (urinary) concentration of
catecholamines, HVA and MHPG are non-informative
most probably due to dopamine production by residual
TH and tyrosinase activity in non-neuronal tissues
(Willemsen et al., 2010). Elevated serum prolactin may,
however, be used as a peripheral biomarker reﬂecting cen-
tral neurotransmitter status (Aitkenhead and Heales, 2013).
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The release of this hormone from the pituitary gland is
under control of hypothalamic dopamine, which is the pri-
mary physiological inhibitor of prolactin secretion
(Ben-Jonathan, 1985). Furthermore, galactorrhoea has
been observed in some severely affected hyperprolactinae-
mic patients with THD (Yeung et al., 2006). To date, 70
THD patients have been reported (www.biopku.org/pnddb)
(Willemsen et al., 2010; Fossbakk et al., 2014); the
most recurrent TH mutation, accounting for 30% of all
mutant alleles, is c.698G4A/p.Arg233His in exon 6;
NM_1999292.2 (corresponding to c.605G4A/
p.Arg202His in hTH1). While as a homozygous or com-
pound heterozygous allele this mutation can be associated
with type A or type B THD (Haavik et al., 2008;
Willemsen et al., 2010), about half of the patients with
type B THD are homozygous for variant p.R233H
(Willemsen et al., 2010).
Parkinsonian syndromes, dystonias, and related move-
ment disorders showing a reduction in the levels of TH
activity and dopamine levels are closely associated with
THD (Kurian et al., 2011; Garcia-Cazorla and Duarte,
2014). Although THD is not accompanied by neurodegen-
eration, it shares several traits with Parkinson’s disease
where the motor features actually reﬂect the loss of striatal
dopamine due to degeneration of dopaminergic neurons in
the midbrain (Obeso et al., 2010). Transgenic mouse
models aiming to mimic THD by inactivating the Th
gene have been generated in the past (Kobayashi et al.,
1995; Zhou et al., 1995; Szczypka et al., 1999). The com-
plete Th knock-out was non-viable, and none of the rescue
mutants fully reproduced the clinical and pathological fea-
tures of THD. They did, however, provide valuable insights
into the importance of dopamine and the other catechol-
amines for mouse foetal development (Kobayashi et al.,
1995; Zhou et al., 1995) and the functional interdepend-
ence of the adrenomedullary and adrenocortical systems
(Bornstein et al., 2000).
To provide novel insights into catecholamine function
and study the pathophysiological mechanisms responsible
for the severe (type B) THD phenotype, we generated a
constitutive Th knock-in mouse with the p.Arg203His
mutation, equivalent to the human TH-p.R233H (hTH1-
p.R202H). This mouse, here termed Th knock-in, was
viable and presented with motor dysfunction due to a
reduced TH activity and gradual loss of catecholamine
metabolites, including dopamine. Measurements in brain
extracts, immunohistochemical analyses and kinetic and
molecular studies of wild-type and mutant human and
mouse enzymes showed the instability of the mutant TH.
Importantly, the mutant enzymes could not be stabilized by
dopamine, highlighting the importance of a functional
regulatory feedback inhibition by catecholamines to main-
tain TH levels and proper localization. Furthermore, the Th
knock-in mouse displays the salient clinical features of
human type B THD phenotype including biochemical mar-
kers, impaired motor function, diurnal ﬂuctuation of symp-
toms and non-responsiveness to L-DOPA treatment, and
thus represents an ideal model for pathomechanistic studies
and for investigations of novel therapeutic approaches,
such as pharmacological chaperones and treatment strate-
gies based on circadian regulation of TH activity and/or
restorative properties of sleep.
Materials and methods
Generation of the Th knock-in mouse
allele
A C57BL/6 mouse carrying a constitutive knock-in of the
point mutation p.Arg203His in the Th gene was custom gen-
erated by TaconicArtemis (NCBI gene ID 21823, transcript
variant Th-1 NM_0093771.1; Ensembl gene ID
ENSMUSG00000000214). Details on the targeting vector for
electroporation, homologous recombination and selection in
mouse embryonic stem cells (Art B6/3.6 background C57BL/6
NTac) are given in Supplementary Fig. 1A–C. Validation of
correct and single targeting was done by Southern blot and
PCR analyses (details on request). For elimination of the
NeoR cassette, mice were crossed with a FLP-deleter strain
[C57BL/6-Tg(CAG-Flpe)1 Arte] for random integration of the
CAGGS-FLPe transgene, and subsequently mice were crossed to
homozygosity.
Genotyping of Th knock-in mice
One primer set was used for testing for the presence of an
additional 85 bp FRT sequence by fragment size analysis (pri-
mers ‘For’ 4601_33: 5’-GAGCTCCCAGAATTGACAGC-3’;
‘Rev’ 4601_34: 5’-GATCACACTCCACCATATCAAGG-3’)
and another set for the presence of the R203H mutation via
Sanger sequencing (primers 4602_35: 5’-TGTCAGAGTTGGA
TAAGTGTCACC-3’ and 4602_36: 5’-TGACAGCTAACCA
GTCACCTCC-3’; see also Supplementary Fig. 1B and C).
Standard PCR conditions were used for DNA ampliﬁcation.
Mouse husbandry and treatment
studies
Animal experiments were performed in accordance with the
guidelines and policies of the Veterinary Ofﬁce of the State
of Zurich and Swiss law on animal protection, the Swiss
Federal Act on Animal Protection (1978), and the Swiss
Animal Protection Ordinance (1981). Animal studies received
approval from the Cantonal Veterinary Ofﬁce, Zurich, and the
Cantonal Committee for Animal Experiments, Zurich,
Switzerland. All mice are generated by back-crossing with
C57BL/6J from the Jackson Laboratory (i.e. C57BL/6J,
-synuclein positive), and for controls, we exclusively used
the wild-type littermates. Mice were maintained in a humidity
and temperature (21–23C) controlled environment under a
12-h dark–light cycle. For treatment studies, six tablets con-
taining L-DOPA (levodopa 100mg) and the decarboxylase in-
hibitor carbidopa (25mg) were purchased (Sinemet) and
diluted in 20ml of double distilled H2O. For validation, the
ﬁnal concentration of L-DOPA was determined by high perfor-
mance liquid chromatography (Blau et al., 1999). Newborn
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homozygous Th knock-in and wild-type control mice were fed
for the chronic experiments daily per os with a solution con-
taining 10mg levodopa plus 2.5mg carbidopa per kg of body
weight and per day for a time period of up to 3 weeks of age.
Elevation of brain 3-OMD (3-O-methyldopa) and HVA con-
trol supported that mice received adequate doses of L-DOPA
(Fig. 7). Treated mice were tested 24 h after the last adminis-
tration for motor behaviour, and at sacriﬁce, tissue was col-
lected for biochemical analyses. Mock control, independent
groups of Th knock-in and wild-type mice, sex and age-
matched, were given double distilled H2O in parallel. For the
acute L-DOPA treatment experiment, a group of Th knock-in
plus wild-type control mice were ﬁrst mock fed and tested for
motor function (rotarod and bar test; see below). Following a
resting phase of 2–3 h, all mice were loaded per os with a
single bolus of a solution containing 10mg levodopa plus
2.5mg carbidopa per kg of body weight, before retesting
these mice for motor coordination within 20–45min after
the L-DOPA loading.
Metabolic cage analysis
Locomotion, food and water intake, O2 consumption and CO2
production were determined for single housed mice (females at
the age of 9 months) during a 24-h period in metabolic cages in
an open-circuit indirect calorimetry system as previously
described (Wueest et al., 2014) (PhenoMaster, TSE Systems).
After being adapted to single caging, mice were placed in cages
closed with air-tight lids. Water bottles and food cups were
placed on scales to measure water and food intake continuously.
The measurements were saved on a computer in 20-min intervals
and were used to calculate cumulative food and water intake.
Activity data were measured using an infrared light-beam. To
measure energy expenditure and respiratory exchange ratio
(RER), ambient air was pumped through the cage via a ﬂow
controller. Air entering and leaving each cage was monitored
for its O2 and CO2 concentration. The cages were connected
to two analysers measuring O2/CO2 concentration of each cage
for a period of 2min in 20-min intervals. Energy expenditure
and respiratory exchange ratio were calculated using the manu-
facturer’s software based on the following equation:
energy expenditure ðkcal=hÞ ¼ 3:941 VO2 þ 1:106 VCO2
1000
;
respiratory exchange ratio ¼ VCO2
VO2
:
Behavioural motor testing
Experiments were carried out during the light phase, between
10 am and 5 pm, and always at the same time of the day
within the same group of animals. Experimental batches
were acclimated to the test room for at least 1–2 days before
testing.
Open ﬁeld test
For the open ﬁeld test (Bello et al., 2011), Plexiglas activity
boxes monitored by a video tracking system (Ethovision,
Noldus) were used to assess total horizontal activity and
mean velocity of locomotion. Animals were placed in a neutral
position of the acrylic boxes (40 40 46 cm) and left to ex-
plore freely and undisturbed for 30min. Boxes were carefully
cleaned between tests to minimize odour cues in the arena.
Bar test
For the Bar test (Noain et al., 2013), spontaneous catalepsy
was determined in Th wild-type and Th knock-in mice using
the horizontal bar test in which the time of immobility (deﬁned
as immobile trunk and limbs) was assessed as described pre-
viously. Brieﬂy, to discard the possibility of confounding freez-
ing behaviour induced by fear/stress with catalepsy, all mice
were habituated to the experimental context by 2min free
exploration over the working bench and experimental setup.
Following this, mice were restrained by the tail, their front
paws placed over the 5-cm elevated bar (1-cm diameter, plexi-
glas) and the back limbs set over the working bench.
Immediately after, the timer was started. A trail was con-
sidered valid when the animal remained grabbing the bar
with the front paws until the timer was running (2 s).
Usually, 2–4 trials were invalid for each mouse at the begin-
ning of the testing session. The highest immobility score out of
ﬁve valid trials was considered for the analysis of both wild-
type and knock-in subjects. The cut-off of the experiment was
set at 180 s.
Rotarod test
For the Rotarod test (Avale et al., 2004), wild-type and Th
knock-in mice were individually placed in a neutral position
on the immobile rotarod treadmill (UgoBasile). Immediately,
the speed was increased to 16 rpm and each mouse was
given a 10-min training session. During the training session
mice were repositioned on the rod after each fall. Mice were
tested 3 h later for 3min at a ﬁxed velocity of 16 rpm, and the
latency to the ﬁrst fall was recorded for each subject.
Gait analysis
For gait analysis (de Medinaceli et al., 1982; Kunkel-Bagden
et al., 1993; Suresh Babu et al., 2012), both hind and fore
paws of mice were inked with non-toxic blue and red ink.
Animals were immediately placed at one end of a 30-cm
acrylic alley, whose ﬂoor was covered in white absorbent
paper, and encouraged to walk to the opposite end. The
paper was then removed and labelled with the animal ID
number for further analysis. The stride length and width
were manually measured and normalized to body weight
(‘size’) of each mouse to obtain short-step and wide-based
gait indices, respectively.
Preparation of whole brain lysates
from mice
Immediately after sacriﬁce, whole brains were resected and
shock frozen in liquid nitrogen. Frozen brains were grinded
to powder under liquid nitrogen; thereafter, all procedures
were carried out at 4C. Powdered brains were ‘dissolved’ in
1ml of homogenization buffer containing 50mM Tris-HCl,
pH 7.5, 100mM KCl, 1mM dithiothreitol (DTT), 0.2mM
PMSF (stock 10mg/ml in isopropanol), 1mM leupeptin
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(stock 5mg/ml in H2O) and 1 mM pepstatin (stock 1mg/ml in
methanol). A TissueLyser II (Qiagen; cat. no. 85300) was used
for preparation of lysate following the manufacturer’s
protocol.
Gene (mRNA) expression studies
Total RNA was extracted from powdered mouse brains by the
QIAmp RNA Blood Mini Kit (Ref. 52304; Hombrechtikon)
and cDNA was produced by the Promega reverse transcription
system (Ref. nr. A3500). Mouse Th, Tph1, Tph2 and Igf1
mRNA expression levels were performed using the commer-
cially available ABI assays (Mm.00447546 for Th mRNA;
NCBI RefSeq NM_009377.1; Mm00493798_m1 for Tph1
mRNA, NCBI RefSeq NM_001136084.1; NM 009414.2;
Mm00557717_m1 for Tph2 mRNA, NCBI RefSeq
NM_173391.2; Mm00439560_m1 for Igf1\ mRNA, NCBI
RefSeq NM_001111274.1). The murine glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) mRNA (ABI assay ID:
Mm99999915_g1; NCBI RefSeq NM_008084.2) was used to
normalize the relative Th, Thp1, and Thp2 mRNA levels.
Values were calculated as described (Livak and Schmittgen,
2001).
Determination of protein, neopterin,
biopterin and monoamine neuro-
transmitter metabolites
Protein concentration (in g/l) was determined by using the M-
TP Mikroprotein kit from Beckman Coulter Synchron LX-
System (Beckman Coulter Inc; kit-no. 445860). Biopterin,
neopterin and monoamine neurotransmitter metabolites were
determined in brain tissue following published protocols (Blau
et al., 1999; Elzaouk et al., 2003).
Total thyroxine, thyroid stimulating
hormone and prolactin
Serum IGF1 was determined by radioimmunoassay (RIA)
using a rat IGF1 RIA kit (DSL-2900, Bu¨hlmann
Laboratories) (Elzaouk et al., 2003), total thyroxine from
whole blood dried on ﬁlter paper was measured with the
‘GSPTM Neonatal Thyroxine kit’ from PerkinElmer (Life and
Analytical Sciences), serum prolactin was quantiﬁed using an
ELISA kit for mouse and rat (GenWay Biotech, Inc), and glu-
cose was measured according to standard methods on a rou-
tine Clinical Chemistry unit on a Beckman Coulter UniCel
DxC 600 (Nyon) following the manufacturer’s instructions.
Measuring blood pressure in mice
A non-invasive computerized tail-cuff system for measuring
systolic blood pressure in mice was applied as described
(Krege et al., 1995).
Tissue preparation and
immunohistochemistry
Adult mice at the age of 6–7 months were anaesthetized with
sodium pentobarbital and, after exsanguination, transcardially
perfused with 4% paraformaldehyde in phosphate-buffered
saline (PBS, pH 7.4). Brains were immediately removed,
post-ﬁxed, cryoprotected in sucrose ladder and stored at 80
C until further use. For free-ﬂoating immunohistochemistry,
brains were cryostat sectioned in 40 mm slices, incubated for
1 h in 1% H2O2 and then washed. A rabbit polyclonal anti-
TH antiserum was used (1:1000; Millipore, AB152) for spe-
ciﬁc immunostainings of TH cells. Sections were incubated
with primary antibody overnight at 4C together with 2%
normal goat serum. After washing, sections were incubated
for 2 h at room temperature with a solution containing bioti-
nylated goat anti-rabbit IgG (1:400, Vector Laboratories).
After washing, sections were incubated for 1 h at room tem-
perature with avidin/biotin complex (1:200, ABC Vectastain
Elite Kit, Vector) and washed twice. Finally, sections were
exposed to a solution of 0.025% diaminobenzidine, 0.05%
H2O2 in Tris-buffered saline buffer and monitored for colour
development under a microscope (Gelman et al., 2003).
Congo red staining was performed over Th wild-type and
Th knock-in brain tissue to determine the presence of amyloid
deposits indicative of a neurodegenerative process (Bohnen and
Jahn, 2013; Catafau and Bullich, 2015). Brieﬂy, we mounted
40-mm cryostat sections and dried them overnight. A 5-min
wash in deionized water was followed by 20min in alkaline
sodium chloride solution and 20min in Alkaline Congo red
solution (Sigma-Aldrich, Cat# HT60). We then dehydrated the
stained tissue in absolute ethanol and xylene, and ﬁnally
mounted them for bright ﬁeld microscopy. We counted TH-
positive cell bodies in the midbrain using a semiquantitative
method. Brieﬂy, substantia nigra pars compacta/ventral teg-
mental area sections from two Th wild-type and two Th
knock-in were randomly selected from a pull of stained
tissue. Similar anatomical levels were included from each geno-
type, to avoid misrepresentation. All positive TH cell bodies
were counted in one hemi-section from each animal.
Additional methodological information is available in the
online Supplementary material.
Results
Th knock-in mice display moderate
growth retardation and hypotension
A constitutive knock-in containing the Th-p.Arg203His
was generated by homologous recombination in the
C57BL/6 background and bred to homozygosity
(Supplementary Fig. 1 and Supplementary Table 1). The
Th knock-in litter size was normal with an expected
Mendelian ratio and an apparently normal phenotype ini-
tially. After weaning, however, Th knock-in mice exhibited
moderate and continuous growth retardation with 25–34%
less body weight compared to their wild-type or heterozy-
gous littermates (Fig. 1A and B). That this was not due to
feeding abnormalities was conﬁrmed quantitatively by
metabolic cage analyses showing normal food intake and
respiratory exchange ratio. Locomotor activity and energy
expenditure were, however, reduced (Supplementary Fig.
2). Follow-up examinations of mutant mice revealed no
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constipation, and a quantitative analysis of the fat and total
energy contents in faeces also revealed no differences be-
tween wild-type and Th knock-in mice, indicating that
mutant mice had normal absorption and digestion (data
not shown). Th knock-in was normoglycaemic and Igf1
gene expression was normal (mRNA of whole brain ex-
tracts; not shown) as were IGF1 serum levels in adult
mice at the age of 12 weeks (Supplementary Fig. 3A). We
noticed however that Igf1 mRNA was signiﬁcantly elevated
in whole brain extracts from Th knock-in mice at the age
of 3 weeks (not shown), implying that the IGF system
might be involved in brain growth, as suggested by
others (Delafontaine et al., 2004). We further detected ele-
vation of the total thyroid hormone thyroxine
(Supplementary Fig. 3B) and hypotension (Supplementary
Fig. 3C) while serum thyroid stimulating hormone was not
different between mutant and control mice (not shown).
Both low body weight and reduced blood pressure are
found in patients with type B THD (Grattan-Smith et al.,
2002; Willemsen et al., 2010) and in mice with norepin-
ephrine and epinephrine deﬁciency (Swoap et al., 2004),
while we found normal levels of catecholamines in the ad-
renals and heart of adult Th knock-in mice (data not
shown), which indicated central regulation for reduced
body weight and hypotension. Normal catecholamine con-
tent in peripheral tissues was also reported for heterozy-
gous Th knock-out mice that present a signiﬁcant
reduction of TH (Kobayashi et al., 1995).
Gradual loss of brain catecholamines
in Th knock-in mice
Whole brain catecholamine and serotonin metabolites were
measured in newborn (Day 1), juvenile (3 weeks) and adult
Figure 1 Sex-speciﬁc differences in body weight between wild-type and Th knock-in mice. (A) Female and (B) male mice fed ad
libitum with standard chow. Growth retardation resulted in reduced body weight, for instance at the age of 12 weeks 25% reduction for females
and 34% reduction for males. Signiﬁcant differences between Th knock-in (ki) and wild-type (wt) combined with heterozygotes mice are indicated:
**P5 0.01; ***P5 0.001 (Student’s two-tailed t-test).
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mice (12 weeks and 1 year). The values of brain dopamine
and other catecholamines and their metabolites obtained
for adult wild-type mice were in a similar range to those
obtained in previous studies (Tho¨ny et al., 2008; Calvo
et al., 2010). HVA, the major biomarker in CSF for TH
deﬁciency in patients, was low in Th knock-in mice at all
ages, whereas L-DOPA, dopamine, norepinephrine and
MHPG were initially normal, but fell continuously there-
after in mutant mice (Fig. 2A–D). This decrease appears
speciﬁc for the catecholamines and their metabolites, as
serotonin, which is typically not compromised in THD,
remained unchanged both with respect to age and when
compared with the values in wild-type mice, and only
at an advanced age, when mutant mice exhibited a
striking loss of catecholamines, was a reduction of the sero-
tonin precursor 5-hydroxytryptophan (5-HTP) observed
(Fig. 2D). Biopterin (and neopterin) content remained
unchanged at all ages (Supplementary Fig. 4), as was the
case for 5-HIAA, thus leading to a reduced HVA:5-HIAA
ratio in Th knock-in mice compared to wild-type mice at
all ages (Supplementary Table 2), similar to what is found
in the CSF of THD patients (Willemsen et al., 2010).
Furthermore, we measured a consistent elevation of serum
prolactin levels in adult mutant mice reﬂecting central
dopamine deﬁciency (Supplementary Fig. 3D) that caused
reduced fertility of Th knock-in females (not shown),
although galactorrhoea was not observed.
Early motor dysfunction and diurnal
ﬂuctuation of the motor deﬁcits in Th
knock-in mice
A moderate reduction of motor activity was observed in
mutant mice during metabolic cage analyses
(Supplementary Fig. 2C). To explore the nature of this
motor dysfunction, we performed a series of behavioural
tests assessing spontaneous catalepsy, motor coordination,
amount and velocity of spontaneous locomotion, and gait
characteristics at different ages. Motor function was tested
in juvenile (3 weeks old), young adult (11 weeks old) and
1-year-old mutant male mice plus sex and age-matched
wild-type controls (Fig. 3A–F). In the bar test, Th knock-
in mice showed increased time of immobility compared to
controls, indicating spontaneous catalepsy, a sign of rigidity
and inability to initiate movements. In addition, when
placed at the bar, Th knock-in mice of all ages, but par-
ticularly older adults, presented an abnormal body posture
and muscle twitching, suggesting the presence of a dystonic
component, while we did not observe clasping of the hind-
limbs by the vertical tail suspension assay as a common test
for a dystonic phenotype in mice (Sato et al., 2008).
Th knock-in male mice challenged in the rotarod test
showed a signiﬁcantly reduced latency to fall, indicating
impaired motor coordination. In the open ﬁeld test,
Figure 2 Gradual loss of brain monoamine neurotransmitter metabolites in Th knock-in mice. (A) Newborn mice, 1 day, (B)
juvenile mice, 3 weeks, (C) adult mice, 12 weeks, and (D) adult mice, 1 year. Data for Th wild-type mice are shown in black and Th knock-in in
grey. Monoamine neurotransmitter metabolites are depicted in pmol/mg of total brain protein. 3-OMD = 3-O-methlydopa; 5-HTP = 5-
hydroxytryptophane. Signiﬁcant difference from the corresponding wild-type value is indicated by asterisks: *P5 0.05; **P5 0.01; ***P5 0.001
(Student’s two-tailed t-test).
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Th knock-in mice showed signiﬁcantly reduced levels of
horizontal activity (amount and velocity of spontaneous
locomotion), indicating a hypokinetic and bradykinetic
phenotype. Next, we analysed the characteristics of gait
(normalized to body weight to compensate for the size
difference between genotypes). Mutant mice had an
increased stride width per body weight index compared
to normal controls, suggestive of a signiﬁcant wide-based
gait. This was conﬁrmed by a generalized disorganization
of the gait, including dragging marks, changes in direction
and freezing (data not shown). In contrast, Th knock-in
mice did not show abnormal stride length, as observed by
an unchanged stride length per body weight index
compared to controls. In summary, while the catecholamine
deﬁciency increased with age (Fig. 2A–D), the severe
motor dysfunction was present from the ﬁrst measurements
at 3 weeks onwards, and its severity appeared independent
of age.
Figure 3 Motor function tests of mutant (Th knock-in) and wild-type (Th-wild-type) male mice at different ages. (A) Bar test for
assessment of catalepsy. (B) Rotarod test for determination of motor coordination. (C) Total distance travelled in the open ﬁeld test. (D) Mean
velocity of locomotion in the open ﬁeld test. (E) Gait analysis to test for stride width normalized to body weight. (F) Gait analysis to test for
short-step disorder (stride length normalized to body weight). Th wild-type mice are shown in black and Th knock-in in grey. Signiﬁcant difference
from the corresponding wild-type value is indicated: **P5 0.01; ***P5 0.001 (Student’s two-tailed t-test or ANOVA for ﬂuctuation bar test).
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Marked diurnal ﬂuctuation of motor behaviour is a hall-
mark in patients with THD (Willemsen et al., 2010;
Haugarvoll and Bindoff, 2011). To determine whether
the motor performance in mutant mice varied throughout
the day, we performed the bar test at 8 am and 8 pm in the
same set of animals and found that Th knock-in mice
performed signiﬁcantly better after the resting period (at
8 pm, note the inverted circadian rhythms of mice
compared to humans) than after the activity period (at 8
am), while wild-type controls presented a stable
performance at both times (Willemsen et al., 2010;
Haugarvoll and Bindoff, 2011) (Fig. 4).
Gradual reduction of TH protein and
activity in brain of Th knock-in mice,
with speciﬁc loss of TH in striatum
Gene expression of Th, Tph1 and Tph2 (mRNAs) in whole
brain extracts of Th knock-in mice was similar to that in
wild-type mice at different ages, and no particular hetero-
geneity was observed for transcript numbers in either mice.
Th mRNA transcripts (but not Tph1 and Tph2 mRNAs)
showed an increase of 50% from newborn (1 day) to
3 weeks for both wild-type and Th knock-in mice
(Supplementary Table 1). On the other hand, immuno-
quantiﬁcation of TH protein content in whole brain
extracts showed a remarkable 5-fold increase in TH relative
to total protein from newborn to 3 weeks in normal mice,
but no signiﬁcant increase in TH protein was measured in
this period for Th knock-in (Fig. 5A and B). For wild-type
mice, TH content was maintained from 3 weeks up to
1 year, but Th knock-in revealed a gradual loss of
TH protein relative to the normal (wild-type) content,
reaching a value as low as 3% of wild-type TH protein
in 1-year-old animals (Fig. 5B, inset). The speciﬁc TH
activity in brain extracts under standard conditions,
measured by a sensitive radiochemical assay (Reinhard
et al., 1986), also followed a similar development as
the protein content for the wild-type animals (the activ-
ity increased from 1.6  0.6 to 5.3  1.0 pmol L-DOPA/
mg/min from Day 1 to 3 weeks, a value that was
maintained up to 1 year). However, the activity in
Th knock-in brain extracts was below the sensitivity thresh-
old and could not be determined accurately by the radio-
chemical assay or other methods tested, including HPLC
and ﬂuorimetric detection of L-DOPA (Haavik and
Flatmark, 1980).
Loss of TH was also observed by immunohistochemical
staining for TH of the substantia nigra pars compacta and
ventral tegmental area region and corpus striatum on cor-
onal brain sections from perfused adult male Th knock-in
and wild-type mice (6–7 months old). As seen in Fig. 5C we
observed a similar expression pattern of TH in Th knock-in
and control mice in the substantia nigra pars compacta/
ventral tegmental area, with some less dense stained pro-
jections, whereas in the corpus striatum we observed an
almost complete lack of immunoreactive processes.
Furthermore, higher magniﬁcation photomicrographs
depict a similar soma staining in the midbrain of mutants
and controls whereas reduced staining of processes is again
observed for the mutants (Fig. 5D). A semiquantitative
TH+ cell count performed in the substantia nigra pars
compacta/ventral tegmental area of mutant and control
brains indicated no decrease of immunoreactive TH cells
in the midbrain of the mutants (220.5  35.5 and
232.5  35.5 for Th knock-in and Th wild-type mice, re-
spectively). Together with the lack of aberrant amyloid de-
position in either midbrain or corpus striatum, as indicated
by Congo red staining in these brain areas (Fig. 5E), the
histological results strongly support lack of neurodegenera-
tion in the midbrain of mutant animals. Rather, our results
support the reduction in the amount of TH protein
measured by immunoquantiﬁcation and revealed a
marked mislocalization of TH, consistent with a defective
transport of mTH-R203H across the nigrostriatal projec-
tion (see below).
The misfolding loss-of-function
mutations hTH1-R202H and
mTH-R203H are not stabilized by
dopamine
To better understand the TH dysfunction in THD patients
and in Th knock-in mice, we studied the molecular and
kinetic effects of the mutation in the human (h) and
mouse (m) TH enzymes, using puriﬁed, tetrameric,
Figure 4 The bar test for catalepsy reveals diurnal ﬂuctu-
ation of motor deﬁcits. Bar test performed at 8 am (black bars)
and 8 pm (grey bars) to explore potential ﬂuctuations in catalepsy
severity. While there was no difference for Th wild-type mice
performance at different day times, Th knock-in mice exhibited a
signiﬁcant difference between morning and evening (*P5 0.05; two-
way ANOVA for ﬂuctuation bar test). The overall difference
between genotypes conﬁrms the results shown in Fig. 3A (indicated
by the three asterisks; ***P5 0.001; Student’s two-tailed t-test).
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recombinant hTH1-wt, mTH-wt, hTH1-R202H and mTH-
R203H. First we analysed the substrate and cofactor-
dependent activity of each enzyme (Supplementary Fig.
5A and B); the steady state activity constants are summar-
ized in Table 1. Compared with hTH1-wt, mTH-wt
showed reduced speciﬁc activity, but a similar Km(BH4),
slightly decreased S0.5(L-Tyr) (higher substrate afﬁnity for
L-Tyr) and reduced substrate inhibition constant (Ksi),
denoting stronger substrate inhibition. The mutants
hTH1-R202H and mTH-R203H showed decreased Vmax
and Km(BH4) and slight increase of S0.5(L-Tyr) compared
with their corresponding wild-type counterparts, indicating
a clear, but not severe kinetic defect. On the other hand, an
evident destabilizing misfolding of the mutant enzymes was
indicated by a 10-fold lower yield of puriﬁed tetrameric
mutant enzymes expressed in E. coli, compared with the
wild-type forms. Decreased protein stability of the hTH1-
R202H mutant is also predicted by the FoldX algorithm
Figure 5 TH protein content in brain from Th-wild-type and Th knock-in mice. (A) Representative immunoblots of brain extracts of
mice at the age of 1 day, 3 weeks, 12 weeks and 1 year; kDa, standard; mTH, puriﬁed mouse TH; wild-type (Th-wild-type) and ki (Th knock-in)
mice. (B) TH protein content in brain extracts from Th wild-type (black bars) and Th knock-in mice (grey bars), as density of the 59 kDa TH band
relative to the intensity of the GAPDH band. Inset: Percentage of TH protein content (grey bars) in brain extracts of Th knock-in versus Th wild-
type mice. Signiﬁcant difference between mice at different ages with mice at 1 day is indicated: *P5 0.001 (Student’s two-tailed t-test). (C–E)
Immunohistochemical and Congo red staining of TH in brain of Th-wild-type and Th knock-in mutant mice, at the age of 6–7 months. (C)
Substantia nigra pars compacta (SNpc)/ventral tegmental area (VTA) of Th wild-type and Th knock-in mice present a similar degree of staining
indicating lack of neurodegeneration in the mutant mice, while a striking lack of TH staining was observed in the corpus striatum in Th knock-in
mice compared to wild-type control mice, indicating a largely reduced amount of TH protein in these neuronal processes. (D) Higher magni-
ﬁcation view of midbrain TH+ cell bodies at different levels (top and middle panels) and inset images depicting the higher density of processes
staining in Th wild-type compared to Th knock-in brains (bottom panel). (E) Congo red staining in mutant and wild-type controls. The scale bars
represent 0.5mm (C and E left), 1.1mm (E, right), and 100 mm (D).
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(Schymkowitz et al., 2005), which estimated a destabiliza-
tion energy of 9.96 kcal/mol (G) based on the tetra-
meric structure of hTH (PDB 2XSN), including the
catalytic and tetramerization domains. To corroborate
that the mutation caused the destabilization, we performed
differential scanning ﬂuorimetry (DSF) analyses. This
method was chosen due to the small amounts of protein
required, as protein was limited for the mutants. The
mutant enzymes showed reduced stability compared with
the respective wild-type forms [2–3C decreased midpoint
denaturation (Tm)-values; Fig. 6A]. Although signiﬁcant,
the decreased thermodynamic stability caused by the muta-
tion could not, however, fully explain the relative decay of
TH protein in the Th knock-in compared to the wild-type
mouse (Fig. 5). Additional defects in regulatory stabiliza-
tion of the mutant mTH-R203H enzyme might explain this
relative loss of TH protein in the mutant mouse.
Stabilization of TH by dopamine and other catecholamines
is an important regulatory mechanism, which leads to com-
petitive inhibition of TH activity versus the BH4 cofactor,
and provides a natural chaperone effect that prevents
degradation of the enzyme (Okuno and Fujisawa, 1991;
Sumi-Ichinose et al., 2001; Tho¨ny et al., 2008). In vitro,
this stabilization is manifested by an increase in the
Tm-values and a decrease in its susceptibility to proteolysis
(Martinez et al., 1996; McCulloch and Fitzpatrick, 1999).
As expected, hTH1-wt and mTH-wt were stabilized by
dopamine binding, increasing their Tm-values up to 3
C
(Fig. 6A and B), but the mutants were not stabilized by
dopamine (Fig. 6C and D). In addition, dopamine protected
the wild-type enzymes, but not the mutants, from limited
tryptic proteolysis (shown for hTH1 in Fig. 6E–K).
Non-responsiveness of Th knock-in
mice to L-DOPA treatment
We determined the effect of chronic and acute L-DOPA
treatment on the motor outcome of juvenile or young
adult Th knock-in mice and controls. In the chronic tests,
catalepsy and motor coordination were investigated after
daily L-DOPA (plus carbidopa) or mock treatment from
birth to 3 weeks of age using a high dose according to rec-
ommendations for THD in humans (i.e. 10mg/kg/day of L-
DOPA) (Willemsen et al., 2010). No signiﬁcant differences
were found either in the bar test or rotarod performance in
Th knock-in mice given L-DOPA or vehicle (Supplementary
Fig. 6A and B). Similar negative results were obtained from
treating adult Th knock-in mice over a period of 12 days
(not shown). Nevertheless, monoamine neurotransmitter
analysis in brain extracts of sacriﬁced mice showed signiﬁ-
cant metabolite improvement following L-DOPA treatment
(Fig. 7A), although TH protein was not increased (Fig.
7B). Similarly, in an acute test for motor coordination
(rotarod) and catalepsy or rigidity (bar test) upon a single
dose of L-DOPA (10mg per kg body weight plus carbidopa),
Th knock-in mice did not show any differences in perform-
ance before and 20–45min after administration
(Supplementary Fig. 6C and D), corroborating non-respon-
siveness of Th knock-in mice to L-DOPA treatment.
Discussion
The Th knock-in mouse was generated to provide an experi-
mental in vivo model to investigate TH and catecholamine
deﬁciency both in terms of disease pathogenesis and the
effect of mutations on enzyme function and regulation
in vivo. In the longer term, this model appears valuable to
test treatments aimed at improving diseases related to loss of
dopamine. The model is clinically robust. The Th knock-in
mouse appears normal at birth, but thereafter exhibits mod-
erate failure to thrive, motor abnormalities including abnor-
mal body posture and twitching, i.e. dystonia-like features,
reduced coordination, hypokinesia, ataxia and catalepsy or
rigidity-akinesia. There is also clear diurnal variation of the
motor defects and lowered blood pressure, as found in THD
patients homozygous for p.Arg233His (Willemsen et al.,
2010). The biochemical and other abnormalities in the
Th knock-in mice include an early and persistent decrease
in brain dopamine and noradrenaline to critically low levels,
associated with low brain TH, which together with a
Table 1 Steady-state kinetic parameters for recombinant puriﬁed human TH1 (hTH1) and mouse TH (mTH)
wild-type (wt) forms, and the respective mutants hTH1-R202H and R203H
Enzyme BH4 L-Tyr
Vmax Km (BH4) Vmax S0.5(L-Tyr) Ksi
a
(nmol of L-DOPA/minmg) (mM) (nmol of L-DOPA/minmg) (mM) (mM)
hTH1-wt 400  11 50  6 782  41 22  1 54  5
mTH-wt 252  14* 47  10 583  46* 15  1* 28  4*
hTH1-R202H 162  3* 34  3* 344  50* 28  3 60  9
mTH-R203H 132  3** 21  2** 280  40** 23  5 49  6**
For BH4 concentration dependency, data were ﬁt to the Michaelis-Menten model and for L-Tyr concentration dependency to the substrate inhibition model.
aKsi, substrate inhibition constant.
* P5 0.05 with respect to corresponding values for hTH1-wt.
** P5 0.05 with respect to corresponding values for mTH-wt.
See also Supplementary Fig. 5. Results are means  SD for three different experiments.
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reduced body weight and hyperprolactinaemia are character-
istics of THD. Th knock-in mice were notably homogeneous
with respect to all parameters determined in this work,
including motor dysfunction, biochemical phenotype and un-
responsiveness to L-DOPA, which probably reﬂects the gen-
etic background homogeneity of these inbred strains.
Patients homozygous for p.Arg233His actually show
higher phenotypic variability (Willemsen et al., 2010),
which might point to THD as a complex trait autosomal
recessive disorder where the phenotype might be modulated
at different steps of the catecholaminergic systems, reﬂecting
a higher complexity in human than mice.
Previous mice models have not mirrored THD to the
same degree as the here presented Th knock-in mouse.
Both the Th-/- and the dopamine b-hydroxylase-deﬁcient
Dbh-/- knock-out mice have a high pre- and perinatal mor-
tality due to cardiovascular failure associated with the lack
of norepinephrine, and conﬁrm the importance of catechol-
amines for foetal development (Kobayashi et al., 1995;
Thomas et al., 1995; Zhou et al., 1995). TH function
and norepinephrine synthesis could be rescued in noradre-
nergic neurons of transgenic Th-/- mice. These dopamine-
deﬁcient mice survive for a short period without treatment
(Willemsen et al., 2010; Garcia-Cazorla and Duarte, 2014),
but have normal norepinephrine levels and are thus imper-
fect models for THD. The aromatic amino acid decarboxyl-
ase knock-out mouse is catecholamine-deﬁcient and shows
a 50% survival, but shows in addition seriously reduced
serotonin levels (Lee et al., 2013) and is also not a model to
investigate the pathogenic mechanisms of speciﬁc TH
deﬁciency.
Newborn Th knock-in mice show normal values of cat-
echolamines and other metabolites, except for a reduction
in HVA. By 3 weeks of age, however, we observed a drop
in brain norepinephrine that, despite its crucial role in
mouse foetal development (Thomas et al., 1995), did not
affect pup survival. Initially, the reduction in norepineph-
rine was not accompanied by any signiﬁcant decrease in
dopamine, pointing to compensatory mechanisms that
maintain dopamine levels e.g. by downregulation of its
Figure 6 The stability of recombinant puriﬁed human TH1 (hTH1) and mouse TH (mTH) and the respective mutants R202H
and R203H, and effect of dopamine. (A–D) Differential scanning ﬂuorimetry proﬁles (ﬂuorescence at 610 nm versus temperature) for hTH1-
wt (A), mTH-wt (B), hTH1-R202H (C) and mTH-R203 (D), analysed at a concentration of 0.9mM subunit without (solid black line) and with (dotted
line) equimolar amount (0.9 mM) of dopamine. The midpoint denaturation (Tm)-values, determined as maximal temperature in ﬁrst-derivatives, are
shown in the corresponding plots. (E) SDS-PAGE showing the limited tryptic digestion of hTH1-wt (lanes 1–5) and hTH1-R202H (lanes 6–10) in the
absence (2, 3, 7, 8) and the presence (4,5,9,10) of 50mM dopamine; 1 and 6 are the respective controls in the absence of trypsin. Conditions: 2.5mM
subunit hTH1 or hTH1-R202H were incubated with trypsin for 30 s (2, 4, 7, 9) or 60 s (3, 5, 8, 10) at 25C, at a TH:trypsin ratio of 200:1. The gels
were stained with Coomassie Brilliant Blue and the raw area of the bands was measured using the Image Lab 3.0.1 software, and represented for lanes
1, 3, 5, 6, 8 and 10 in F,G,H, I, J and K, respectively. At the selected conditions, hTH1-wt (apparent molecular weight of 59 kDa), was trypsinized into
two truncated forms of 57 and 54kDa, both lacking the N-terminal peptide MPTPDATTPQAKGFR (analyses by LC–MS/MS spectroscopy; data not
shown).
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degradation (Tunbridge et al., 2006). Concomitant to their
defective brain noradrenaline content, Th knock-in mice
fail to accomplish the 5-fold increase in TH protein
observed for the Th wild-type mice from newborn to 3
weeks of age (Fig. 5B), despite the presence of normal
(similar to wild-type) levels of Th-mRNA (Supplementary
Table 1). A similar substantial increase in TH in the same
postnatal period has been reported, and this increase
appears critical for the correct development of the dopa-
minergic system and the psychomotor function (Homma
et al., 2011). This ﬁnding is supported by our results show-
ing early and persistent motor dysfunction in the Th knock-
in mice. The postnatal increase in TH protein in normal
mice is not only driven by upregulated transcription
(Supplementary Table 1) but through stabilization of the
TH protein, where both the level of BH4 and catechol-
amines themselves have been shown to be implicated in
the stabilization (Homma et al., 2011, 2013). BH4 levels
are similar in Th wild-type and knock-in mice, and the
Km(BH4) for the mutant enzymes indicates a relative high
afﬁnity for the cofactor (Table 1). Catecholamine binding
and feedback inhibition of TH occur in competition with
BH4 (Nagatsu, 1995; Daubner et al., 2011), and thus the
enzyme kinetics data are in accord with a mutation-
associated structural change in TH that leads to opposite
effects for BH4 and dopamine, and to defective stabilization
by dopamine (or norepinephrine; data not shown). Despite
some recent insights on residues important for catechol-
amine binding at the catalytic domain (Briggs et al.,
2014), a structural explanation for the defective stabiliza-
tion by dopamine in the mutants must await the determin-
ation of high resolution structures of full-length TH,
including the regulatory domain, where the determinants
for high afﬁnity binding are located (McCulloch and
Fitzpatrick, 1999; Nakashima et al., 1999). The hTH1-
R202H and mTH-R203 mutants show both kinetic
(Table 1) and stability defects (Fig. 6), but the lack of dopa-
mine stabilization of mutant TH emerges as a deleterious
regulatory deﬁciency that explains the lack of accumulation
of TH protein in the critical postnatal period in the Th
knock-in mice (Fig. 5A and B). Defective stabilization by
catecholamines may also support the speciﬁc deﬁcit of TH
expression in the striatum (Fig. 5C and D) as proper trans-
port of TH to this brain area also requires the stabilization
of the enzyme (Homma et al., 2013). Mutation-associated
defective trafﬁcking and aberrant localization of protein
cargos is a recurrent pathological mechanism in neuro-
logical and neurodegenerative disorders (Hung and Link,
2011; Encalada and Goldstein, 2014). Little is known
about mechanisms of transport of TH and dopamine in
the dopaminergic nigrostriatal pathway projecting from
the substantia nigra pars compacta to the caudate-putamen
(striatum), although it is accepted that at least in adrenergic
neuronal systems, TH is fast transported along the axon in
an anterograde fashion to the terminals (Brimijoin and
Wiermaa, 1977). Accordingly, impaired axonal transport
of TH in dopaminergic projections has recently been
shown to be associated with parkinsonism and drastic
Figure 7 Outcome of L-DOPA treatment of Th knock-in mice on brain monoamine neurotransmitter metabolites and TH
protein. Mutant Th knock-in (ki) and Th wild-type (wt) mice were treated from Day 1 after birth onwards for a period of 3 weeks with L-DOPA
(10mg/kg/day) plus carbidopa (2.5mg/kg/day) or vehicle (ddH20 control); inset, L-DOPA in pmol/mg protein. (A) Brain monoamine neuro-
transmitter metabolites. (B) TH protein relative to GAPDH is shown for Th wild-type and Th knock-in mice with or without L-DOPA/carbidopa
treatment. In both A and B, signiﬁcant difference from the corresponding wild-type value is indicated: *P5 0.05; **P5 0.01; ***P5 0.001
(Student’s two-tailed t-test).
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reduction of TH and dopamine levels in striatal synapses
(Ittner et al., 2008). It is thus very probable that the
observed motor dysfunction in the Th knock-in mice is
caused by defective TH protein transport leading to
scarce TH and dopamine in synaptic terminals to activate
dopamine receptors in the caudate-putamen.
Lack of or poor responsiveness to L-DOPA is manifested
by a large number of patients with THD type B, particu-
larly those with the hTH1-R202H mutation (Grattan-Smith
et al., 2002; Willemsen et al., 2010). One interesting ﬁnd-
ing of the present study is that the motor dysfunction of the
Th knock-in mice is not improved by standard L-DOPA
supplementation even when treated from the ﬁrst day of
life. Other mouse models with dopamine deﬁciency show
a partial recovery with dopamine treatment, especially in
features such as feeding problems. Motor improvement is,
however, often incomplete (Zhou and Palmiter, 1995),
reﬂecting perhaps the developmental deﬁciencies in the
foetal and perinatal periods (Zhou and Palmiter, 1995;
Homma et al., 2011). Possible neurodevelopment disorders
associated with defective stabilization by catecholamines
and consequent mislocalization of TH cannot be ruled
out as the reason for the lack of DOPA-responsiveness of
the motor dysfunction in the Th knock-in mice, despite the
apparent correction of L-DOPA levels and increase of dopa-
mine in brain extracts observed after treatment (Fig. 7).
Developing novel non-L-DOPA-based therapeutic strategies
for THD type B may thus be an attractive approach, espe-
cially for patients with the speciﬁc hTH-R233H mutation.
In this respect, emerging therapies based on protein stabil-
ization, e.g. pharmacological chaperones, appear promis-
ing, as we have previously shown in in vitro experiments
that the variant hTH1-R202H can be stabilized by com-
pounds with chaperone potential (Calvo et al., 2010; Hole
et al., 2015). Furthermore, the diurnal ﬂuctuation of motor
deﬁcits is deﬁnitively an important hallmark of our Th
knock-in mutant mouse and may also be exploited in the
search for novel treatment strategies based on the restora-
tive potential of either circadian regulation of TH activity
and/or restorative properties of sleep.
Finally, the growth retardation measured in the Th
knock-in mutant mouse in combination with normal food
intake, normoglycaemia and apparent reduced energy
expenditure in the metabolic cage deserves explanation.
Surviving mice with selective dopamine deﬁciency in dopa-
minergic neurons, but not in noradrenergic neurons, exhibit
abnormal feeding behaviour including swallowing difﬁcul-
ties (aphagy) (Zhou and Palmiter, 1995; Szczypka et al.,
1999), symptoms we did not observe in the Th knock-in
mice. On the other hand, growth retardation in combin-
ation with normal food intake has also previously been
found in total and neuron-speciﬁc dopamine-receptor
knock-out mice, which shows reduced dopamine signalling
(Baik et al., 1995; Noain et al., 2013). Like these other
surviving TH-deﬁcient mice with reduced noradrenergic
activity, the Th knock-in mice presented here showed low-
ered resting metabolic rate with respect to wild-type mice.
Furthermore, it has become increasingly clear that isolated
dopaminergic abnormalities and parkinsonian syndromes
involve abnormal or increased energy expenditure during
walking and motor tasks which may explain the reduction
in growth of mutant mice despite comparable food intake
with wild-type mice (Molero-Luis et al., 2013; Amano
et al., 2014).
In conclusion, there is a large spectrum of phenotypes in
patients with THD, resulting from diverse deﬁciencies in
absolute and relative dopamine and norepinephrine levels
with different impact on systemic and motor function
(Willemsen et al., 2010). This variability would depend
on the catalytic, conformational and regulatory defects of
the particular TH mutation. In agreement with severely
affected patients homozygous for the mutation p.R233H,
Th knock-in mice studied in this work present severe motor
deﬁciencies from a juvenile age onwards, and these
abnormalities are apparently not corrected by classical re-
placement treatment with L-DOPA. The mutant hTH1-
R202H and mTH-R203H proteins are not stabilized by
dopamine, leading to intracellular instability, gradual loss
of TH activity and altered nigro-striatal distribution, aiding
to interpret the biochemical and locomotor phenotype of
Th knock-in. In addition, to contribute to the understand-
ing of the biochemical pathogenesis of catecholamine deﬁ-
ciency, this mouse model offers a useful platform for
designing and evaluating new routes to disease therapies
not only for THD, but also other genetic and idiopathic
dopaminergic deﬁciencies.
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